[({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2S,3S,4S,5R,6S)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphinic acid

• ChemBase编号: 3078
• 分子式: C17H27N3O17P2
• 平均质量: 607.353702
• 单一同位素质量: 607.08156968
• SMILES: CC(=O)N[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[P@@](=O)(O)O[P@@](=O)(O)OC[C@@H]1O[C@H]([C@H](O)[C@H]1O)n1ccc(=O)[nH]c1=O
• Canonical SMILES: OC[C@@H]1O[C@@H](O[P@](=O)(O[P@](=O)(OC[C@@H]2O[C@H]([C@@H]([C@H]2O)O)n2ccc(=O)[nH]c2=O)O)O)[C@H]([C@@H]([C@H]1O)O)NC(=O)C
• InChI: InChI=1S/C17H27N3O17P2/c1-6(22)18-10-13(26)11(24)7(4-21)35-16(10)36-39(31,32)37-38(29,30)33-5-8-12(25)14(27)15(34-8)20-3-2-9(23)19-17(20)28/h2-3,7-8,10-16,21,24-27H,4-5H2,1H3,(H,18,22)(H,29,30)(H,31,32)(H,19,23,28)/t7-,8-,10-,11-,12-,13-,14+,15+,16-/m0/s1
• InChIKey: LFTYTUAZOPRMMI-LSIJYXAZSA-N

名称和登记号

名称

• IUPAC标准名: [({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2S,3S,4S,5R,6S)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphinic acid
• IUPAC传统名: {[(2S,3R,4R,5R)-5-(2,4-dioxo-3H-pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy[(2S,3S,4S,5R,6S)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphosphinic acid
• 别名: Uridine-Diphosphate-N-Acetylglucosamine

登记号

• PubChem SID: 46506870; 160966522
• PubChem CID: 46936661

理论计算性质

JChem

• Acid pKa: 1.7172135
• 质子受体: 14
• 质子供体: 9
• LogD (pH = 5.5): -9.71149
• LogD (pH = 7.4): -10.033719
• Log P: -5.284643
• 摩尔折射率: 117.5571 cm^3
• 极化性: 48.479454 Å^3
• 极化表面积: 300.41 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -1.41
• LOG S: -1.72
• 溶解度: 1.14e+01 g/l

详细说明

DrugBank - DB03397

Drug information: experimental